# Neflamapimod PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/neflamapimod

> The next catalyst for neflamapimod, sponsored by CervoMed Inc. (CRVO), is its trial start, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for neflamapimod?

The next catalyst for neflamapimod, sponsored by CervoMed Inc. (CRVO), is its trial start, Q1 2027. Press release filed with the SEC (EX-99): "ALS: CervoMed expects dosing of the first patient with neflamapimod in the EXPERTS-ALS trial, which will evaluate neflamapimod for the treatment of ALS, in the first quarter of 2027." [Calendar and source filings](https://sec-api.dev/pdufa/neflamapimod)

Source: Press release filed with the SEC (EX-99), accession 0001437749-26-035885, https://www.sec.gov/Archives/edgar/data/1053691/000143774926035885/ex_1041172.htm (retrieved 2026-11-12). Last confirmed 2026-11-09. Cite: https://sec-api.dev/pdufa/neflamapimod#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | neflamapimod |
| Codes |  |
| Sponsor | CervoMed Inc. (CRVO) https://sec-api.dev/companies/crvo/catalysts |
| Indications | dlb, enriched for those without ad co-pathology, dementia with lewy bodies in second half of 2026, subject to financing, [frontotemporal dementia](https://sec-api.dev/indications/frontotemporal-dementia), dlb funded primarily, early-stage dementia with lewy bodies, early-stage dlb in october 2024 and remain |
| Modality |  |
| FDA designations | fast track, orphan |

## Timeline

### Aug 2023: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: DLB funded primarily.
- First seen 2025-03-17, last confirmed 2025-03-17.
- SEC Form 10-K (accession 0001437749-25-007829): "In the second quarter of 2023, we initiated our ongoing RewinD-LB Trial, a Phase 2b clinical trial of neflamapimod in participants with DLB funded primarily by a $21.3 million grant from the NIA, and, in August 2023, we announced dosing of the first patient in the trial." https://www.sec.gov/Archives/edgar/data/1053691/000143774925007829/crvo20241231_10k.htm

### Aug 2024: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2024-11-12, last confirmed 2026-06-22.
- SEC prospectus (424B) (accession 0001437749-26-021218): "In August 2024, we initiated a Phase 2a study in Strasbourg, France, which will evaluate neflamapimod in up to 20 DLB patients with mild cognitive impairment (MoCA score >= 18 during screening)." https://www.sec.gov/Archives/edgar/data/1053691/000143774926021218/crvo20260619c_424b5.htm
- SEC Form 10-K (accession 0001437749-26-008259): "In August 2024, we initiated a Phase 2a trial in Strasbourg, France, to evaluate a twice daily regimen (80mg BID) of neflamapimod in 26 patients with DLB with MCI (MoCA score ≥ 18 during screening)." https://www.sec.gov/Archives/edgar/data/1053691/000143774926008259/crvo20251231_10k.htm
- SEC Form 10-K (accession 0001437749-26-008259): "In August 2024, we initiated a Phase 2a study in Strasbourg, France, to evaluate a twice daily regimen (80mg BID) of neflamapimod in up to 25 patients with DLB with MCI (MoCA score ≥ 18 during screening)." https://www.sec.gov/Archives/edgar/data/1053691/000143774926008259/crvo20251231_10k.htm
- SEC prospectus (424B) (accession 0001437749-25-016167): "In August 2024, we initiated a Phase 2a study in Strasbourg, France, which will evaluate neflamapimod in up to 20 DLB patients with mild cognitive impairment (MoCA score >= 18 during screening)." https://www.sec.gov/Archives/edgar/data/1053691/000143774925016167/crvo20250510_424b5.htm
- SEC Form 10-K (accession 0001437749-25-007829): "In August 2024, we initiated a Phase 2a trial in Strasbourg, France, to evaluate a twice daily regimen (80mg BID) of neflamapimod in up to 25 patients with DLB with MCI (MoCA score >= 18 during screening)." https://www.sec.gov/Archives/edgar/data/1053691/000143774925007829/crvo20241231_10k.htm
- SEC Form 10-K (accession 0001437749-25-007829): "In August 2024, we initiated a Phase 2a study in Strasbourg, France, to evaluate a twice daily regimen (80mg BID) of neflamapimod in up to 25 patients with DLB with MCI (MoCA score >= 18 during screening)." https://www.sec.gov/Archives/edgar/data/1053691/000143774925007829/crvo20241231_10k.htm
- SEC Form 10-Q (accession 0001437749-24-034344): "In August 2024, we initiated a Phase 2a study in Strasbourg, France, to evaluate neflamapimod in up to 20 patients with mild cognitive impairment (MoCA score >= 18 during screening)." https://www.sec.gov/Archives/edgar/data/1053691/000143774924034344/crvo20240930_10q.htm

### Dec 2024: topline data readout

- Status: scheduled. Date confidence: month. Stage: 2. Indication: early-stage dementia with Lewy bodies.
- First seen 2024-11-13, last confirmed 2024-11-27.
- Press release filed with the SEC (EX-99) (accession 0001437749-24-034889): "- Reported last patient, last visit in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB) in October 2024; topline data expected in December 2024 -" https://www.sec.gov/Archives/edgar/data/1053691/000143774924034889/ex_747440.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-24-034889): "Reported last patient, last visit had occurred in the Phase 2b RewinD-LB clinical trial evaluating oral neflamapimod in patients with early-stage DLB in October 2024 and remain on track to report topline data from the study in December 2024." https://www.sec.gov/Archives/edgar/data/1053691/000143774924034889/ex_747440.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-24-036335): "On track to report topline data from the RewinD-LB Phase 2b clinical trial in early-stage dementia with Lewy bodies (DLB) in December 2024" https://www.sec.gov/Archives/edgar/data/1053691/000143774924036335/ex_752882.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-24-034889): "We look forward to leveraging their extensive experience as we approach topline data from the RewinD-LB study in December 2024 and prepare for regulatory discussions and Phase 3 initiation in mid-2025."" https://www.sec.gov/Archives/edgar/data/1053691/000143774924034889/ex_747442.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-24-036335): "Topline results from the RewinD-LB study are expected in December 2024." https://www.sec.gov/Archives/edgar/data/1053691/000143774924036335/ex_752882.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-24-034889): "We remain on track to report topline data from the study in December 2024," said John Alam, MD, Chief Executive Officer of CervoMed." https://www.sec.gov/Archives/edgar/data/1053691/000143774924034889/ex_747440.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-24-034889): "Topline data from RewinD-LB are expected in December 2024." https://www.sec.gov/Archives/edgar/data/1053691/000143774924034889/ex_747441.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-24-034889): "The study includes 43 sites (32 in the United States, eight in the United Kingdom, and three in the Netherlands) and completed enrollment in June 2024, with topline data expected in December 2024." https://www.sec.gov/Archives/edgar/data/1053691/000143774924034889/ex_747440.htm

### Dec 2024: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2025-05-12, last confirmed 2026-06-22.
- SEC prospectus (424B) (accession 0001437749-26-021218): "We believe we are a leader in the industry in developing a treatment for DLB, as we are the only company of which we are aware with an asset that has shown statistically significant improvements compared to placebo in a Phase 2a clinical trial (our AscenD-LB Trial) and has initiated a Phase 2b clinical evaluation (our ongoing RewinD-LB Trial), from which we expect topline results in December 2024." https://www.sec.gov/Archives/edgar/data/1053691/000143774926021218/crvo20260619c_424b5.htm
- SEC prospectus (424B) (accession 0001437749-25-016167): "We believe we are a leader in the industry in developing a treatment for DLB, as we are the only company of which we are aware with an asset that has shown statistically significant improvements compared to placebo in a Phase 2a clinical trial (our AscenD-LB Trial) and has initiated a Phase 2b clinical evaluation (our ongoing RewinD-LB Trial), from which we expect topline results in December 2024." https://www.sec.gov/Archives/edgar/data/1053691/000143774925016167/crvo20250510_424b5.htm

### Q1 2025: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2025-01-31, last confirmed 2025-01-31.
- Press release filed with the SEC (EX-99) (accession 0001437749-25-002329): ""Our next data readout, from the first 16 weeks of the OLE phase of the trial, will be available in the first quarter of 2025 and will include data on a range of global, cognitive and motor efficacy endpoints, as well as pharmacokinetic data, obtained from a sizeable subgroup of participants who are receiving capsules of neflamapimod manufactured more recently than the capsules utilized during the double-blind phase of the study." https://www.sec.gov/Archives/edgar/data/1053691/000143774925002329/ex_772642.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-002329): "Topline data from the first 16 weeks of the OLE phase of the RewinD-LB trial are expected in 1Q 2025." https://www.sec.gov/Archives/edgar/data/1053691/000143774925002329/ex_772642.htm

### Q2 2025: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: frontotemporal dementia.
- First seen 2024-11-13, last confirmed 2025-05-12.
- Press release filed with the SEC (EX-99) (accession 0001437749-25-008249): "In the second quarter of 2025, CervoMed plans to initiate the Phase 2 Restore Trial to evaluate neflamapimod in patients recovering from ischemic stroke." https://www.sec.gov/Archives/edgar/data/1053691/000143774925008249/ex_791644.htm
- SEC Form 10-K (accession 0001437749-25-007829): "We believe neflamapimod may promote neurologic recovery, particularly of motor function, in patients recovering from certain types of strokes and expect to initiate our Restore Trial, a Phase 2 trial evaluating neflamapimod in patients recovering from ischemic stroke, in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1053691/000143774925007829/crvo20241231_10k.htm
- SEC Form 10-K (accession 0001437749-25-007829): "Based upon these data and hypotheses, we plan to initiate our Restore Trial, a Phase 2 trial evaluating neflamapimod in up to 90 participants recovering from ischemic stroke, in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1053691/000143774925007829/crvo20241231_10k.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-008249): "In November 2024, the U.S. Food and Drug Administration (FDA) granted neflamapimod Orphan Drug designation for the treatment of frontotemporal dementia (FTD) and CervoMed plans to initiate a Phase 2a trial evaluating neflamapimod in the nonfluent/agrammatic variant of primary progressive aphasia - a subtype of FTD - in mid-2025." https://www.sec.gov/Archives/edgar/data/1053691/000143774925008249/ex_791644.htm
- SEC Form 10-Q (accession 0001437749-25-015966): "The increase of $2.0 million was primarily due to the increase in costs related to CMC activities, increased non-clinical studies, increased headcount costs, and outsourced CRO costs related to clinical work for neflamapimod, including start-up costs related to our planned Phase 2a clinical trials in recovery after ischemic stroke (the Restore Trial) and the nonfluent/agrammatic variant of PPA, a subtype of FTD, which we intend to initiate in the second quarter of 2025 and mid-2025, respectively." https://www.sec.gov/Archives/edgar/data/1053691/000143774925015966/crvo20250331_10q.htm
- SEC Form 10-K (accession 0001437749-25-007829): "In November 2024, the FDA granted neflamapimod Orphan Drug designation for the treatment of FTD and we plan to initiate a Phase 2a trial evaluating neflamapimod in the nonfluent/agrammatic variant of PPA - a subtype of FTD - in mid-2025." https://www.sec.gov/Archives/edgar/data/1053691/000143774925007829/crvo20241231_10k.htm
- SEC Form 10-K (accession 0001437749-25-007829): "Based in part on these results, in November 2024, the FDA granted neflamapimod orphan drug designation for the treatment of FTD and we plan to initiate a Phase 2a trial evaluating neflamapimod in up to 20 participants with the nonfluent/agrammatic variant of PPA in mid-2025." https://www.sec.gov/Archives/edgar/data/1053691/000143774925007829/crvo20241231_10k.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-24-034889): "While our core focus remains on the opportunity in DLB, we also plan to initiate a Phase 2a trial to evaluate neflamapimod's potential to promote recovery from ischemic stroke in the first quarter of 2025, for which we recently obtained ethics committee approval."" https://www.sec.gov/Archives/edgar/data/1053691/000143774924034889/ex_747440.htm

### 2H 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-11-07, last confirmed 2026-11-09.
- Press release filed with the SEC (EX-99) (accession 0001437749-26-008611): "Multiple potential catalysts anticipated in the second half of 2026, including initiation of the planned Phase 3 trial, topline data from Phase 2a ischemic stroke recovery trial, initial topline data from Phase 2a primary progressive aphasia trial, and initiation of EXPERTS-ALS trial in Amyotrophic Lateral Sclerosis" https://www.sec.gov/Archives/edgar/data/1053691/000143774926008611/ex_933983.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-035885): "RAS: CervoMed expects to obtain topline data from its Phase 2a RESTORE trial evaluating neflamapimod in patients recovering from acute ischemic stroke by the end of 2026." https://www.sec.gov/Archives/edgar/data/1053691/000143774926035885/ex_1041172.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-026771): "RAS: CervoMed expects to report topline data from its Phase 2a RESTORE trial evaluating neflamapimod in patients recovering from acute ischemic stroke in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1053691/000143774926026771/ex_1002031.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-017637): "Recovery After Stroke (RAS): CervoMed expects to complete treatment in the Phase 2a RESTORE trial evaluating neflamapimod in patients recovering from acute ischemic stroke in mid-2026 and to report topline data from the trial in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1053691/000143774926017637/ex_964814.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-008611): "RAS: CervoMed expects to complete enrollment in its ongoing Phase 2a RESTORE trial evaluating neflamapimod in patients recovering from acute ischemic stroke in mid-2026 and to report topline data from the trial in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1053691/000143774926008611/ex_933983.htm
- SEC Form 10-Q (accession 0001437749-25-033879): "Based upon this potential, we have commenced our ongoing RESTORE Trial, a Phase 2 trial evaluating neflamapimod in up to 90 participants recovering from ischemic stroke, from which we expect topline data in the second half of 2026, and our Phase 2a trial evaluating neflamapimod in up to 20 participants with the nonfluent/agrammatic variant of PPA, a subtype of FTD, from which we expect initial biomarker data in mid-2026." https://www.sec.gov/Archives/edgar/data/1053691/000143774925033879/crvo20250930_10q.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-034095): "Initial biomarker data from Phase 2a trial in a sub-type of frontotemporal dementia (FTD) and topline results from Phase 2a trial in recovery after stroke expected in 2026" https://www.sec.gov/Archives/edgar/data/1053691/000143774925034095/ex_885764.htm
- SEC Form 10-K (accession 0001437749-26-008259): "During 2025, we initiated Phase 2a clinical trials in nfvPPA and RAS, from which we expect initial biomarker results and topline clinical results in mid-2026 and the second half of 2026, respectively, subject to available funding to continue operations." https://www.sec.gov/Archives/edgar/data/1053691/000143774926008259/crvo20251231_10k.htm
- SEC Form 10-K (accession 0001437749-26-008259): "We anticipate completing enrollment at the end of the second quarter of 2026 and expect to report topline data in the second half of 2026, subject to available funding." https://www.sec.gov/Archives/edgar/data/1053691/000143774926008259/crvo20251231_10k.htm

### 2H 2026: interim data readout

- Status: scheduled. Date confidence: half.
- First seen 2026-03-17, last confirmed 2026-05-18.
- Press release filed with the SEC (EX-99) (accession 0001437749-26-017637): "The Company also expects to report initial biomarker data from the trial in mid-2026 and initial topline 24-week biomarker and clinical and data from the trial in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1053691/000143774926017637/ex_964814.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-008611): "The Company also expects to report initial biomarker data from the trial in mid-2026 and initial topline clinical data from the trial in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1053691/000143774926008611/ex_933983.htm

### Q1 2027: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: DLB, enriched for those without AD co-pathology.
- First seen 2025-03-18, last confirmed 2026-11-09.
- Press release filed with the SEC (EX-99) (accession 0001437749-26-035885): "ALS: CervoMed expects dosing of the first patient with neflamapimod in the EXPERTS-ALS trial, which will evaluate neflamapimod for the treatment of ALS, in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1053691/000143774926035885/ex_1041172.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-035885): "The Company also expects dosing of the first patient with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1053691/000143774926035885/ex_1041172.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-033943): "The Company also expects to initiate the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1053691/000143774926033943/ex_1034224.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-017637): "Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with Dementia with Lewy Bodies in second half of 2026, subject to financing" https://www.sec.gov/Archives/edgar/data/1053691/000143774926017637/ex_964814.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-017637): "DLB: CervoMed [has initiated clinical site startup activities in the U.S. utilizing internal resources and] plans to initiate a Phase 3 trial evaluating neflamapimod in patients with DLB in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1053691/000143774926017637/ex_964814.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-008611): ""We are now looking ahead to a catalyst-driven 2026, including initiation of the planned Phase 3 trial evaluating neflamapimod in DLB in the second half of 2026, subject to available financing." https://www.sec.gov/Archives/edgar/data/1053691/000143774926008611/ex_933983.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-008611): "DLB: CervoMed plans to initiate a Phase 3 trial evaluating neflamapimod in patients with DLB in the second half of 2026, subject to obtaining sufficient funding." https://www.sec.gov/Archives/edgar/data/1053691/000143774926008611/ex_933983.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-004555): "CervoMed's recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in DLB patients who have a low likelihood of AD co-pathology, and the Company plans to initiate a global, pivotal Phase 3 trial in the same patient population in the second half of 2026, subject to available funding." https://www.sec.gov/Archives/edgar/data/1053691/000143774926004555/ex_922363.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-037025): "CervoMed's recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in DLB patients who have a low likelihood of AD co-pathology, and the Company plans to initiate a global, pivotal Phase 3 trial in the same patient population in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1053691/000143774925037025/ex_896196.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-034095): "CervoMed's recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in DLB patients who have a low likelihood of AD co-pathology, and the Company plans to initiate a global, pivotal Phase 3 trial in the same patient population in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1053691/000143774925034095/ex_885764.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-032869): "CervoMed's recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in DLB patients who have a low likelihood of AD co-pathology, and the Company plans to initiate a global, pivotal Phase 3 trial in the same patient population in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1053691/000143774925032869/ex_882257.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-032184): "CervoMed's recently completed, successful Phase 2b RewinD-LB trial evaluated neflamapimod in DLB patients who have a low likelihood of AD co-pathology, and the Company plans to initiate a global Phase 3 trial in the same patient population in mid-2026." https://www.sec.gov/Archives/edgar/data/1053691/000143774925032184/ex_878763.htm

### Q1 2027: interim data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2026-08-10, last confirmed 2026-08-10.
- Press release filed with the SEC (EX-99) (accession 0001437749-26-026771): "The Company also expects to report initial topline clinical data, as well as additional biomarker data, in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1053691/000143774926026771/ex_1002031.htm

### Q1 2027: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2026-10-13, last confirmed 2026-10-13.
- Press release filed with the SEC (EX-99) (accession 0001437749-26-032502): "We look forward to presenting 24-week biomarker data at the Clinical Trials on Alzheimer's Disease conference in November, followed by topline clinical data in the first quarter of 2027."" https://www.sec.gov/Archives/edgar/data/1053691/000143774926032502/ex_1024863.htm

### Q2 2027: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2026-11-09, last confirmed 2026-11-09.
- Press release filed with the SEC (EX-99) (accession 0001437749-26-035885): "The Company expects to report initial 24-week clinical data, as well as additional biomarker data, at the Alzheimer's & Parkinson's Diseases Conference in March 2027, and full topline data from the trial in the second quarter of 2027." https://www.sec.gov/Archives/edgar/data/1053691/000143774926035885/ex_1041172.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/neflamapimod.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Neflamapimod PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/neflamapimod

```bibtex
@misc{secapidev_pdufa_neflamapimod_20261116,
  title        = {Neflamapimod PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/neflamapimod}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_neflamapimod_20261116","title":"Neflamapimod PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/neflamapimod","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
